The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
61 / 177
Overall Ranking
174 / 4730
Industry
Pharmaceuticals
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
44.686
Target Price
+84.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.75% year-on-year.
Undervalued
The company’s latest PE is -16.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.44M shares, decreasing 0.43% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 6.40M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.78.
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.